Blue Jet Healthcare Limited (NSE:BLUEJET)

Market Cap	78.49B -38.4%
Revenue (ttm)	9.47B -8.0%
Net Income	2.48B -18.8%
EPS	14.29 -18.8%
Shares Out	173.47M
PE Ratio	31.67
Forward PE	26.23
Dividend	1.20 (0.27%)
Ex-Dividend Date	Sep 19, 2025

Volume	149,511
Open	454.65
Previous Close	452.50
Day's Range	440.00 - 457.80
52-Week Range	325.00 - 1,027.80
Beta	0.94
Analysts	Buy
Price Target	501.00 (+12.23%)
Earnings Date	May 25, 2026

About Blue Jet Healthcare

Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norw...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1968
• Employees: 196
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BLUEJET

Financial Performance

In fiscal year 2026, Blue Jet Healthcare's revenue was 9.47 billion, a decrease of -8.03% compared to the previous year's 10.30 billion. Earnings were 2.48 billion, a decrease of -18.80%.

Analyst Summary

According to 5 analysts, the average rating for BLUEJET stock is "Buy." The 12-month stock price target is ₹501.00, which is an increase of 12.23% from the latest price.

Price Target

₹501.00

(12.23% upside)

Analyst Consensus: Buy